JP2017523178A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017523178A5 JP2017523178A5 JP2017504104A JP2017504104A JP2017523178A5 JP 2017523178 A5 JP2017523178 A5 JP 2017523178A5 JP 2017504104 A JP2017504104 A JP 2017504104A JP 2017504104 A JP2017504104 A JP 2017504104A JP 2017523178 A5 JP2017523178 A5 JP 2017523178A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- mds
- alkyl
- use according
- alkynyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *C(C1[C@@](CC2)O[C@@]2C1C(N1CC*CC1)=O)=O Chemical compound *C(C1[C@@](CC2)O[C@@]2C1C(N1CC*CC1)=O)=O 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462028729P | 2014-07-24 | 2014-07-24 | |
| US62/028,729 | 2014-07-24 | ||
| US201462029327P | 2014-07-25 | 2014-07-25 | |
| US62/029,327 | 2014-07-25 | ||
| PCT/US2015/041714 WO2016014783A1 (en) | 2014-07-24 | 2015-07-23 | Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018232414A Division JP6862404B2 (ja) | 2014-07-24 | 2018-12-12 | 骨髄異形成症候群を治療するためのタンパク質ホスファターゼ２ａ阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017523178A JP2017523178A (ja) | 2017-08-17 |
| JP2017523178A5 true JP2017523178A5 (enExample) | 2018-08-30 |
| JP6453441B2 JP6453441B2 (ja) | 2019-01-16 |
Family
ID=55163749
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017504104A Expired - Fee Related JP6453441B2 (ja) | 2014-07-24 | 2015-07-23 | 骨髄異形成症候群を治療するためのタンパク質ホスファターゼ２ａ阻害剤 |
| JP2018232414A Expired - Fee Related JP6862404B2 (ja) | 2014-07-24 | 2018-12-12 | 骨髄異形成症候群を治療するためのタンパク質ホスファターゼ２ａ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018232414A Expired - Fee Related JP6862404B2 (ja) | 2014-07-24 | 2018-12-12 | 骨髄異形成症候群を治療するためのタンパク質ホスファターゼ２ａ阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US10071094B2 (enExample) |
| EP (1) | EP3171870B1 (enExample) |
| JP (2) | JP6453441B2 (enExample) |
| CN (1) | CN106572989B (enExample) |
| WO (2) | WO2016014778A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010147612A1 (en) | 2009-06-18 | 2010-12-23 | Lixte Biotechnology, Inc. | Methods of modulating cell regulation by inhibiting p53 |
| CA2877167A1 (en) | 2012-06-29 | 2014-01-03 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes |
| EP2983661B1 (en) | 2013-04-09 | 2024-05-29 | Lixte Biotechnology, Inc. | Formulations of oxabicycloheptanes and oxabicycloheptenes |
| US10071094B2 (en) | 2014-07-24 | 2018-09-11 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes |
| AU2016219853B2 (en) | 2015-02-19 | 2019-05-16 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders |
| DK3294287T3 (da) | 2015-05-15 | 2020-06-08 | Lixte Biotechnology Inc | Oxabicycloheptan-prodrugs |
| EP3407887B1 (en) * | 2016-01-27 | 2021-09-01 | Lixte Biotechnology, Inc. | Clinical regimen for treating myelodysplastic syndrome with phosphatase inhibitor |
| MX2019006694A (es) | 2016-12-08 | 2019-08-21 | Lixte Biotechnology Inc | Oxabicicloheptanos para la modulacion de la respuesta inmunitaria. |
| CN113694071B (zh) * | 2021-08-31 | 2025-08-15 | 上海交通大学医学院附属瑞金医院 | 清除和/或溶解衰老细胞和/或抑制细胞衰老的化合物用于治疗精神障碍 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US7189740B2 (en) * | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| US7879569B2 (en) * | 2004-11-09 | 2011-02-01 | The Trustees Of The University Of Pennsylvania | Methods for diagnosis of myelodysplastic syndromes (MDS) |
| CA2641308A1 (en) | 2006-02-06 | 2007-08-16 | Lixte Biotechnology Holdings, Inc. | Use of phosphatases to treat tumors overexpressing n-cor |
| WO2008030617A2 (en) * | 2006-09-07 | 2008-03-13 | Stemline Therapeutics, Inc. | Cancer therapy with cantharidin and cantharidin analogs |
| CA2676422C (en) | 2007-02-06 | 2018-10-16 | Lixte Biotechnology Holdings, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
| US20090035292A1 (en) | 2007-08-03 | 2009-02-05 | Kovach John S | Use of phosphatases to treat neuroblastomas and medulloblastomas |
| EA018618B1 (ru) | 2007-10-01 | 2013-09-30 | Ликсте Байотекнолоджи, Инк. | Ингибиторы hdac |
| WO2010147612A1 (en) | 2009-06-18 | 2010-12-23 | Lixte Biotechnology, Inc. | Methods of modulating cell regulation by inhibiting p53 |
| CA2730148C (en) | 2008-08-01 | 2018-04-03 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
| EP2309853A4 (en) | 2008-08-01 | 2012-04-25 | Lixte Biotechnology Inc | METHOD FOR CELL MITITULATING BY INHIBITION OF SERIN / THREONINE PHOSPHATASE |
| US8227473B2 (en) | 2008-08-01 | 2012-07-24 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
| US20120135522A1 (en) | 2009-06-18 | 2012-05-31 | Kovach John S | Methods of modulating cell regulation by inhibiting p53 |
| WO2011094683A2 (en) * | 2010-01-29 | 2011-08-04 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Method of identifying myelodysplastic syndromes |
| US20140235649A1 (en) | 2011-05-24 | 2014-08-21 | Lixte Biotechnology, Inc. | Use of phosphatase inhibitors or histone deacetylase inhibitors to treat diseases characterized by loss of protein function |
| WO2013056211A2 (en) | 2011-10-13 | 2013-04-18 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Telomerase reverse transcriptase deficience as diagnostic marker of myelodysplastic syndrome |
| CA2877167A1 (en) | 2012-06-29 | 2014-01-03 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes |
| JP6262225B2 (ja) * | 2012-06-29 | 2018-01-17 | リクスト・バイオテクノロジー，インコーポレイテッド | オキサビシクロヘプタン類、および再灌流障害の治療のためのオキサビシクロヘプタン類 |
| US9738933B2 (en) | 2012-12-05 | 2017-08-22 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | RNF41 as a biomarker predicting response to lenalidomide in non-del(5q) MDS |
| WO2014137741A1 (en) | 2013-03-05 | 2014-09-12 | Lixte Biotechnology, Inc. | Hdac inhibitors for treating traumatic brain injury |
| EP2968279A4 (en) | 2013-03-15 | 2016-09-28 | Lixte Biotechnology Inc | SANGUINARIN ANALOG PPC2 HEMMER FOR CANCER TREATMENT |
| EP2983661B1 (en) | 2013-04-09 | 2024-05-29 | Lixte Biotechnology, Inc. | Formulations of oxabicycloheptanes and oxabicycloheptenes |
| JP2016538281A (ja) | 2013-11-15 | 2016-12-08 | リクスト・バイオテクノロジー，インコーポレイテッド | 血液脳関門を通過するタンパク質ホスファターゼ阻害剤 |
| WO2015196073A1 (en) | 2014-06-20 | 2015-12-23 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for the treatment of ovarian cancer |
| US10071094B2 (en) * | 2014-07-24 | 2018-09-11 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes |
| WO2016040877A1 (en) | 2014-09-12 | 2016-03-17 | Lixte Biotechnology, Inc. | Human dosing of phosphatase inhibitor |
| WO2016061193A1 (en) | 2014-10-15 | 2016-04-21 | Lixte Biotechnology, Inc. | Process of synthesizing 3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1] heptane-2-carboxylic acid |
| AU2016219853B2 (en) | 2015-02-19 | 2019-05-16 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders |
| DK3294287T3 (da) | 2015-05-15 | 2020-06-08 | Lixte Biotechnology Inc | Oxabicycloheptan-prodrugs |
-
2015
- 2015-07-23 US US15/328,235 patent/US10071094B2/en active Active
- 2015-07-23 US US15/328,838 patent/US20170209434A1/en not_active Abandoned
- 2015-07-23 JP JP2017504104A patent/JP6453441B2/ja not_active Expired - Fee Related
- 2015-07-23 WO PCT/US2015/041709 patent/WO2016014778A1/en not_active Ceased
- 2015-07-23 WO PCT/US2015/041714 patent/WO2016014783A1/en not_active Ceased
- 2015-07-23 EP EP15825076.1A patent/EP3171870B1/en not_active Not-in-force
- 2015-07-23 CN CN201580041767.1A patent/CN106572989B/zh not_active Expired - Fee Related
-
2018
- 2018-08-20 US US16/105,479 patent/US10434100B2/en active Active
- 2018-12-12 JP JP2018232414A patent/JP6862404B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017523178A5 (enExample) | ||
| MX2023007192A (es) | Inhibidores de prmt5. | |
| PH12022550783A1 (en) | Antiviral heterocyclic compounds | |
| EA202090514A1 (ru) | Противовирусное средство против гепатита в | |
| EA201201031A1 (ru) | Ингибиторы вируса гепатита с | |
| RU2013119607A (ru) | Полициклические гетероциклические соединения и способы их применения для лечения вирусных заболеваний | |
| EA200971041A1 (ru) | Новые пептидные ингибиторы репликации вируса гепатита с | |
| MX384836B (es) | Agentes antivirales contra la hepatitis b | |
| WO2019143902A3 (en) | Substituted heterocycles as antiviral agents | |
| EA201490377A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата | |
| EA201200890A1 (ru) | Комбинированная терапия hcv | |
| JP2015505564A5 (enExample) | ||
| RU2013155509A (ru) | Применение ингибирования катепсина к для лечения и/или профилактики легочной гипертензии и/или сердечной недостаточности | |
| JO3434B1 (ar) | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري | |
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| EA025948B1 (ru) | КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТ-3-КИНАЗЫ (PI3K) И ИНГИБИТОРА mTOR | |
| JP2016531885A5 (enExample) | ||
| EP3999074A4 (en) | AAV HEART GENE THERAPY FOR CARDIOMYOPATHY IN HUMAN BEINGS | |
| EA202191548A1 (ru) | Ингибиторы плазменного калликреина человека | |
| MA42301B1 (fr) | Sel cristallin de fumarate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl)azétidin-1-yl]-méthanone | |
| JP2011518168A5 (enExample) | ||
| EA202190429A1 (ru) | Биодоступные пероральные дозированные формы | |
| RU2013145869A (ru) | КОМБИНАЦИЯ ОЛИГОНУКЛЕОТИДА АНТИ-КЛАСТЕРИНА С ИНГИБИТОРОМ Hsp90 ДЛЯ ЛЕЧЕНИЯ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ | |
| RU2016149761A (ru) | Производные нуклеозидов для лечения ракового заболевания | |
| Xing et al. | N-myc downstream-regulated gene 4, up-regulated by tumor necrosis factor-α and nuclear factor kappa B, aggravates cardiac ischemia/reperfusion injury by inhibiting reperfusion injury salvage kinase pathway |